FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320884637> ?p ?o ?g. }

• W4320884637 endingPage "161" @default.
• W4320884637 startingPage "147" @default.
• W4320884637 abstract "The addition of two years of abemaciclib treatment to standard adjuvant endocrine therapy in all patients with high risk ER+, HER2- early breast cancer (EBC) has been approved by the US Food and Drug Administration (FDA). Pre-selection of patients with an immediate risk of recurrence within the group of clinically high risk patients using detection of minimal residual disease (MRD) using patient-informed circulating tumor DNA assays during follow-up could enhance efficacy. Here, we investigate the cost-effectiveness of the addition of two years abemaciclib in all high risk HR+, HER2- patients and in MRD-guided high risk patients only.Two semi-Markov models were developed to evaluate the cost-effectiveness of adding two years of abemaciclib compared to standard treatment: 1) abemaciclib all and 2) MRD-guided abemaciclib using MRD-guidance. Data of the MonarchE trial were used to model the invasive disease-free survival (iDFS). Since iDFS and overall survival (OS) data of abemaciclib were currently limited, abemaciclib effects were extrapolated using a favorable, intermediate and unfavorable effect scenario.The addition of abemaciclib in all high-risk EBC patients prolonged iDFS slightly (0.04 additional quality adjusted life years (QALYs)) and led to higher costs compared to standard ET, leading to a high incremental cost effectiveness ratio (ICER) of €1,551,876/QALY. Neither the favorable effect scenario (additional 1.09 QALYs) was cost-effective (ICER €62,935/QALY), using a willingness-to-pay threshold of €50,000/QALY. The MRD-guided abemaciclib strategy resulted in lower costs and an increase in QALYs (1.27) compared to standard treatment in the unfavorable effect scenario.The addition of abemaciclib to adjuvant endocrine therapy in all high-risk ER+, HER2- EBC patients is not cost-effective. However, using MRD detection to justify the addition of abemaciclib treatment dominates standard treatment in this cost-effectiveness analysis. Further evaluation of MRD detection in EBC by means of prospective clinical trials assessing clinical utility is recommended and promising in terms of cost-effectiveness." @default.
• W4320884637 created "2023-02-16" @default.
• W4320884637 creator A5010992160 @default.
• W4320884637 creator A5016822168 @default.
• W4320884637 creator A5038426869 @default.
• W4320884637 creator A5048187760 @default.
• W4320884637 creator A5064453966 @default.
• W4320884637 creator A5066926133 @default.
• W4320884637 creator A5076304683 @default.
• W4320884637 date "2023-02-01" @default.
• W4320884637 modified "2023-09-23" @default.
• W4320884637 title "Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?" @default.
• W4320884637 cites W1570249624 @default.
• W4320884637 cites W1961026612 @default.
• W4320884637 cites W2074479676 @default.
• W4320884637 cites W2104641188 @default.
• W4320884637 cites W2128458647 @default.
• W4320884637 cites W2507833965 @default.
• W4320884637 cites W2767600184 @default.
• W4320884637 cites W2770773573 @default.
• W4320884637 cites W2883192715 @default.
• W4320884637 cites W2905207641 @default.
• W4320884637 cites W2911685734 @default.
• W4320884637 cites W2939548416 @default.
• W4320884637 cites W2947435062 @default.
• W4320884637 cites W2964980115 @default.
• W4320884637 cites W2976415870 @default.
• W4320884637 cites W3120241209 @default.
• W4320884637 cites W3148345241 @default.
• W4320884637 cites W3206169364 @default.
• W4320884637 cites W4206349107 @default.
• W4320884637 cites W4206831982 @default.
• W4320884637 cites W4211123279 @default.
• W4320884637 cites W4220653025 @default.
• W4320884637 cites W4281738617 @default.
• W4320884637 doi "https://doi.org/10.2147/bctt.s387375" @default.
• W4320884637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36814469" @default.
• W4320884637 hasPublicationYear "2023" @default.
• W4320884637 type Work @default.
• W4320884637 citedByCount "0" @default.
• W4320884637 crossrefType "journal-article" @default.
• W4320884637 hasAuthorship W4320884637A5010992160 @default.
• W4320884637 hasAuthorship W4320884637A5016822168 @default.
• W4320884637 hasAuthorship W4320884637A5038426869 @default.
• W4320884637 hasAuthorship W4320884637A5048187760 @default.
• W4320884637 hasAuthorship W4320884637A5064453966 @default.
• W4320884637 hasAuthorship W4320884637A5066926133 @default.
• W4320884637 hasAuthorship W4320884637A5076304683 @default.
• W4320884637 hasBestOaLocation W43208846371 @default.
• W4320884637 hasConcept C121608353 @default.
• W4320884637 hasConcept C126322002 @default.
• W4320884637 hasConcept C143998085 @default.
• W4320884637 hasConcept C207103383 @default.
• W4320884637 hasConcept C44249647 @default.
• W4320884637 hasConcept C530470458 @default.
• W4320884637 hasConcept C71924100 @default.
• W4320884637 hasConceptScore W4320884637C121608353 @default.
• W4320884637 hasConceptScore W4320884637C126322002 @default.
• W4320884637 hasConceptScore W4320884637C143998085 @default.
• W4320884637 hasConceptScore W4320884637C207103383 @default.
• W4320884637 hasConceptScore W4320884637C44249647 @default.
• W4320884637 hasConceptScore W4320884637C530470458 @default.
• W4320884637 hasConceptScore W4320884637C71924100 @default.
• W4320884637 hasLocation W43208846371 @default.
• W4320884637 hasLocation W43208846372 @default.
• W4320884637 hasLocation W43208846373 @default.
• W4320884637 hasLocation W43208846374 @default.
• W4320884637 hasOpenAccess W4320884637 @default.
• W4320884637 hasPrimaryLocation W43208846371 @default.
• W4320884637 hasRelatedWork W1900595920 @default.
• W4320884637 hasRelatedWork W2114624491 @default.
• W4320884637 hasRelatedWork W2154948599 @default.
• W4320884637 hasRelatedWork W2194631636 @default.
• W4320884637 hasRelatedWork W2224319365 @default.
• W4320884637 hasRelatedWork W2793335702 @default.
• W4320884637 hasRelatedWork W2889691785 @default.
• W4320884637 hasRelatedWork W2913113213 @default.
• W4320884637 hasRelatedWork W4210646467 @default.
• W4320884637 hasRelatedWork W4254083861 @default.
• W4320884637 hasVolume "Volume 15" @default.
• W4320884637 isParatext "false" @default.
• W4320884637 isRetracted "false" @default.
• W4320884637 workType "article" @default.